RecruitingHidradenitis Suppurativa (HS)
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Eligible age
18+ yrs
Accepts
All genders
Locations
28 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Sponsor: Incyte Corporation
You may qualify if…
- ✓ Ability to comprehend and willingness to sign a written ICF for the study.
- ✓ Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
- ✓ Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
- ✓ Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- ✓ Willingness to avoid pregnancy or fathering children as defined in the protocol.
- ✓ Willingness and ability to comply with the study Protocol and procedures.
You may not qualify if…
- ✕ Had been permanently discontinued from study treatment during the parent study.
- ✕ Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
- ✕ Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- ✕ Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- ✕ Live, attenuated vaccine.
- ✕ Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
- ✕ Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- ✕ Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
Where it's recruiting
Alabama
Birmingham · Montgomery
Arizona
Phoenix · Tucson
California
Fountain Valley · Fremont · Huntington Beach · Irvine …
Connecticut
Farmington
Florida
Boca Raton · Coral Gables · Hialeah · Hollywood …
Georgia
Cumming · Marietta · Sandy Springs · Stonecrest
Illinois
Chicago · Skokie · West Dundee
Indiana
Indianapolis · West Lafayette
Kansas
Leawood
Kentucky
Bowling Green
Louisiana
Baton Rouge · New Orleans
Maryland
Baltimore · Glenn Dale · Rockville
Source: ClinicalTrials.gov · NCT06855498 · last updated 2026-11-13